BPC-157

Peptide

BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric juice proteins. B-GRADE for tendon healing (6 studies, 180 participants) and gastric ulcer healing (8 studies, 240 participants). C-GRADE for ligament healing, muscle recovery, wound healing, and neuroprotection. CRITICAL CAVEAT: Nearly all evidence is from ANIMAL studies - human clinical trials are extremely limited. Popular in biohacking/sports communities but regulatory status unclear. NOT FDA-approved. Underground/gray market sourcing raises purity and safety concerns.

Quick Answer

What it is

BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric juice proteins. B-GRADE for tendon healing (6 studies, 180 participants) and gastric ulcer healing (8 studies, 240 participants).

Key findings

  • Grade C: Gastric Ulcer Healing (General Gut Health)
  • Grade C: Tendon Healing (Musculoskeletal Health)
  • Grade C: Intestinal Inflammation (General Gut Health)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: BPC-157

Quick Facts: BPC-157

  • Best Evidence:Grade B
  • Conditions Studied:5
  • Research Outcomes:25
  • Key Effect:Musculoskeletal Health
A0
B0
C19
D6
5 conditions · 25 outcomes

Detailed Outcomes

Grade:
Effect:
Size:
Sort:
|
C
Gastric Ulcer Healing
Notable Improvement (mostly animal data)
largeImproves
C
Intestinal Inflammation
Moderate Decrease (mostly animal data)
moderateImproves
C
Tendon Healing
Notable Improvement (mostly animal data)
largeImproves
C
Muscle Injury Recovery
Moderate Improvement (mostly animal data)
moderateImproves
C
Ligament Healing
Moderate Improvement (mostly animal data)
moderateImproves
C
Wound Healing Rate
Moderate Improvement (mostly animal data)
moderateImproves
C
Angiogenesis
4 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
smallImproves
C
Anti-Aging
3 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
smallImproves
C
Corneal/Ocular Health
3 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
D
Anti-Inflammatory Activity
2 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
D
Anti-Cancer Activity
2 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
D
Lipid Profile
2 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
D
Pain
2 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
C
Neuroprotection
Moderate Protection (mostly animal data)
moderateImproves
D
Endothelial Function
Small Improvement (animal data)
smallImproves

Research Citations (69)

BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.
(2025)
PMID: 41155565
Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.
(2025)
PMID: 40005408
Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution.
(2025)
PMID: 40573261
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
(2025)
PMID: 40131143
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.
(2025)
PMID: 40573323
Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT).
(2025)
PMID: 40759852
Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?
(2025)
PMID: 39265666
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
(2025)
PMID: 40789979
Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats.
(2025)
PMID: 39861766
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
(2025)
PMID: 40005999

Related Peptides

TB-500

Peptide

3 shared conditions · 23 outcomes

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino acid peptide present in most human cells. It has been investigated for its potential role in tissue repair, wound healing, and regeneration. Research, primarily in animal models, suggests it may promote angiogenesis, cell migration, and reduce inflammation. Human clinical trials are limited.

GHRP-6

Peptide

3 shared conditions · 13 outcomes

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2) that potently stimulates growth hormone secretion. Developed in the 1980s by Cyril Bowers, it was the first synthetic peptide shown to specifically elicit dose-dependent GH release both in vitro and in vivo. GHRP-6 acts through the ghrelin receptor (GHS-R1a) and CD36 receptor, exhibiting not only GH-releasing properties but also significant cytoprotective, cardioprotective, and wound healing effects. It increases IGF-1 levels, stimulates appetite, and has demonstrated tissue-protective properties in multiple preclinical and clinical studies. While primarily researched for GH deficiency, emerging evidence supports its potential in wound healing, scar prevention, and cardioprotection.

KPV

Peptide

2 shared conditions · 15 outcomes

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) that exhibits potent anti-inflammatory and immunomodulatory properties. Preclinical studies have demonstrated significant efficacy in reducing intestinal inflammation in multiple models of inflammatory bowel disease, including DSS- and TNBS-induced colitis. Unlike full-length α-MSH, KPV's anti-inflammatory action is not primarily melanocortin receptor-mediated but is instead transported into cells via the PepT1 transporter. No human clinical trials have been conducted to date, limiting the evidence to animal and in vitro studies.

Humanin

Peptide

2 shared conditions · 23 outcomes

Humanin (HN) is a 24-amino-acid mitochondrial-derived peptide encoded within the 16S rRNA gene of mitochondrial DNA. Discovered in 2001 from preserved brain tissue of Alzheimer's patients, it demonstrates potent neuroprotective, cytoprotective, and metabolic regulatory effects. Humanin levels decline with age but remain stable in long-lived species and are elevated in offspring of centenarians.